Trend to Acquire and Use Digital Pathology Technology is Still in Earliest Stages
Anatomic pathology laboratories continue to purchase and deploy digital pathology systems at a brisk rate. It is confirmation that ever more pathologists are ready to adopt and use digital pathology systems.
Evidence in support of the digital pathology trend comes from a recent press release by one of the leading firms in this field. On December 15, 2010, Aperio Technologies, Inc. announced that it now has more than 700 digital pathology systems operating in 30 countries.
Second-opinion consults will be handled by UPMC’s sub-specialist pathologists
Here’s a unique anatomic pathology collaboration that crosses international borders and will utilize state-of-the-art digital pathology technology to support subspecialty pathologist consultations between the United States and China.
In recent weeks, the University of Pittsburgh Medical Center (UPMC) disclosed that it will provide a range of healthcare services to what is only described as “the largest pathology laboratory in Shanghai.” Of particular interest to pathologists and clinical laboratory managers in the United States, is the fact that pathologists at UPMC will provide second opinion anatomic pathology services to this as-yet-unnamed Chinese pathology laboratory.
Mass General researchers use metabolomic imaging to accurately diagnose tumors
Pathology laboratories may soon find it possible to identify prostate cancer without a biopsy. A new technology under development at Massachusetts General Hospital demonstrates the potential to improve the accuracy of prostate cancer diagnosis. Some studies have demonstrated that nearly a quarter of initial biopsies of the prostate gland may generate false-negative results because the biopsy specimen failed to extract cells from existing cancerous tumors.
To improve the detection of prostate cancer, researchers at Massachusetts General Hospital (MGH) are investigating a new technique that may give doctors a way to locate even small tumors and to provide an accurate determination of a prostate tumor’s prognosis without using a biopsy.